Thyroid Nodules & Thyroid Cancer

Overview & Definition

A thyroid nodule is a discrete lesion within the thyroid gland, radiologically distinct from the surrounding parenchyma. Nodules are ubiquitous: palpable in about 5 percent of adults and 30 to 50 percent on high-resolution ultrasound, rising to over half of older people at autopsy. Despite their abundance, only 5 to 10 percent harbour malignancy. The entire diagnostic discipline of thyroid nodule medicine is therefore one of selective triage — ultrasound-risk-stratify which nodules warrant fine-needle aspiration, and treat precisely according to the cancer type found. Reassuring the benign majority while unmasking the malignant minority is the heart of the topic.[1][2]

Thyroid cancer arises from one of two cell lineages, and that single embryological fact governs behaviour, marker and treatment. Follicular epithelial cells give rise to the differentiated cancers — papillary and follicular — and to their undifferentiated end-point, anaplastic carcinoma. Parafollicular C cells (neural-crest-derived) give rise to medullary carcinoma. Differentiated cancers produce thyroglobulin, retain the sodium-iodide symporter and so take up radioactive iodine (RAI), and respond to TSH suppression with levothyroxine. Medullary cancer produces calcitonin and carcinoembryonic antigen (CEA), does not concentrate iodine, and is driven by RET proto-oncogene mutations — molecular distinctions that translate directly into the management algorithm.[1]

Classification

Thyroid nodules themselves are classified as benign (colloid nodule, simple or haemorrhagic cyst, benign follicular adenoma, nodular goitre, focal thyroiditis) or malignant, with a clinically critical indeterminate zone that cytology cannot resolve on its own. Malignant nodules divide along cell of origin:[1]

[1]

Epidemiology & Risk Factors

Thyroid nodules are among the commonest of all clinical findings. Palpable prevalence is 5 to 10 percent in adults, but ultrasound-detected prevalence reaches 30 to 50 percent in adults and over 60 percent in older cohorts, with autopsy series detecting nodules in roughly half of all glands. Only 5 to 10 percent of clinically significant nodules are malignant, so the pre-test probability is firmly benign — the discipline lies in identifying the minority.[1][2]

Thyroid cancer is the commonest endocrine malignancy. Its age-adjusted incidence has risen sharply over the last three decades, almost entirely driven by increased detection of small papillary carcinomas through wider use of neck ultrasound, carotid Doppler, CT and MRI — a phenomenon of over-diagnosis rather than a true epidemic. Mortality, in contrast, has been essentially flat, confirming that most newly detected cancers are indolent. Women are affected two to four times more often than men; differentiated cancer peaks between 25 and 65 years, while anaplastic cancer typically presents in those over 60.[1]

Risk factors

Iodine deficiency deserves a special note: endemic goitre regions show a shift toward follicular and anaplastic carcinoma, while iodine-sufficient (or iodine-supplemented) populations show a predominance of papillary carcinoma. Population iodine supplementation has been shown to shift the histological mix towards papillary and away from the more aggressive follicular and anaplastic subtypes.[2]

Pathophysiology

Most thyroid nodules are benign: colloid nodules (the commonest), simple or haemorrhagic cysts, benign follicular adenomas, multinodular goitre, and focal thyroiditis. Malignant transformation proceeds along distinct, well-characterised molecular pathways that have become therapeutically actionable.[1]

Papillary carcinoma (PTC) is driven by activation of the MAPK signalling pathway, most often by BRAF V600E (present in about 45 percent) and RET-PTC rearrangements (about 15 percent, classically after radiation), with RAS mutations in a smaller fraction. The MAPK cascade drives the distinctive nuclear morphology — optically clear ground-glass (orphan Annie-eye) nuclei, nuclear grooves and intranuclear pseudoinclusions — and the laminated calcifications called psammoma bodies. PTC spreads lymphatically to cervical nodes (most often central level VI, then lateral levels III to IV) and only uncommonly haematogenously to lung and bone.[1]

Follicular carcinoma (FTC) arises through a different molecular pathway: RAS mutations and the PAX8-PPAR-gamma fusion. Its histological hallmark is capsular and vascular (capsular-space) invasion — invasion through the tumour capsule and into blood vessels — which is why it cannot be diagnosed reliably on fine-needle aspiration (FNA samples cells, not architecture). FTC spreads haematogenously to bone and lung, with characteristically sparing of regional lymph nodes early on. The Hürthle-cell (oncocytic) variant has more abundant mitochondria-rich cytoplasm, is more aggressive and less avid for radioactive iodine.[1]

Medullary carcinoma (MTC) arises from parafollicular C cells (neural-crest-derived, calcitonin-secreting). Its defining molecular event is a gain-of-function mutation in the RET proto-oncogene: germline in the familial forms (MEN-2A, MEN-2B and familial medullary thyroid carcinoma — together about 25 percent of all MTC), and somatic in roughly half of sporadic cases. The RET M918T mutation (exon 16) confers the most aggressive phenotype and is the hallmark of MEN-2B. C cells produce calcitonin (a sensitive tumour marker) and CEA (a marker of tumour burden and dedifferentiation), and the tumour stroma typically contains amyloid (congophilic on staining). MTC does not produce thyroglobulin and does not concentrate iodine.[1]

Anaplastic carcinoma (ATC) is undifferentiated, comprising pleomorphic spindle, giant and squamoid cells. It is thought usually to arise by dedifferentiation of a pre-existing papillary or follicular cancer, accumulating TP53, TERT promoter and beta-catenin (CTNNB1) mutations that override cell-cycle control. BRAF V600E is often co-present (from the antecedent PTC). ATC is among the most aggressive of all human cancers — rapidly invading trachea, oesophagus, great vessels and overlying skin, with a doubling time often measured in weeks.[1]

Clinical Presentation

The classic presentation is a painless neck lump found by the patient, a partner, or a clinician on routine examination, or detected incidentally on carotid Doppler, neck CT, MRI or PET performed for another reason. Most patients are clinically and biochemically euthyroid — thyroid function tests are done to exclude a hyperfunctioning (hot) nodule rather than to diagnose thyroid status per se.[1]

Examination focuses on features that raise malignancy probability. The high-yield clinical risk features are:[1]

• History of childhood neck irradiation, family history of thyroid cancer or MEN-2, age under 20 or over 70, male sex (cancer is less common in men but more often aggressive when present).
• Growth — rapid enlargement of a previously stable nodule is ominous (and a sentinel clue to anaplastic transformation).
• Consistency — a firm or fixed nodule adherent to trachea or strap muscles.
• Voice — hoarseness, a sign of recurrent laryngeal nerve involvement (one of the strongest single predictors of malignancy).
• Nodes — palpable cervical lymphadenopathy, especially levels II to VI.
• Compression — dysphagia, dyspnoea or stridor from a large or rapidly growing mass. [1]

Atypical presentations are deliberately examined. Medullary carcinoma may present with the calcitonin syndrome (flushing, secretory diarrhoea) or as part of MEN-2 — screen for phaeochromocytoma (hypertensive crises), primary hyperparathyroidism (hypercalcaemia) and the MEN-2B marfanoid phenotype with mucosal neuromas. Anaplastic carcinoma presents dramatically as a rapidly enlarging, hard, painful neck mass in an older patient with systemic deterioration, compressive symptoms and sometimes skin invasion. Thyroid lymphoma arises almost exclusively in long-standing Hashimoto thyroiditis and presents as rapid enlargement of a pre-existing goitre in an older woman. Metastases to the thyroid (kidney, breast, lung, melanoma) may mimic a primary nodule.[1]

Differential Diagnosis

The differential of a thyroid nodule is broad, and the role of imaging and FNA is to triage among them:[1]

The clinically distinguishing question is always: does this nodule carry enough risk to warrant FNA? The next two sections — ultrasound TI-RADS and Bethesda cytology — answer that. [1]

Clinical & Bedside Assessment

A focused thyroid consultation takes five minutes and decides the entire work-up. Take a structured history: age and sex, radiation exposure (childhood neck radiotherapy, repeated childhood X-rays, atomic-survivor exposure), family history of thyroid cancer or MEN-2, tempo of nodule growth, and compressive or voice symptoms. Ask specifically about flushing, diarrhoea and hypertension (MEN-2 / medullary) and hypercalcaemia symptoms (parathyroid).[1]

Examine the patient from the front. Inspect the neck for asymmetry and a palpable mass, then palpate the thyroid from behind while the patient swallows a sip of water (thyroid moves up with swallowing, distinguishing it from other neck masses). Document the nodule's size, consistency (soft, firm, hard), surface (smooth, irregular), mobility (mobile, fixed), tenderness, and relation to the trachea. Then systematically palpate the cervical lymph node chains (levels I to VI), particularly the central (level VI) and jugular (levels III to IV) stations. Assess for tracheal deviation and compressive signs (stridor). Check vocal cord function — clinically through voice quality, and by indirect or flexible laryngoscopy in any patient with hoarseness or before any thyroid surgery (a paralysed cord predicts malignant nerve involvement and changes the surgical plan). Measure blood pressure (phaeochromocytoma screen in suspected MEN-2) and look for hyperparathyroidism (hypercalcaemia) and the marfanoid habitus and mucosal neuromas of MEN-2B.[1]

Investigations

The investigation of a thyroid nodule follows a strict, evidence-based sequence — TSH first, ultrasound second, fine-needle aspiration third, ancillary tests fourth.[1][2]

Step 1 — Serum TSH

Serum TSH is the first test in every thyroid nodule. A normal or raised TSH prompts ultrasound risk-stratification. A suppressed (subnormal) TSH with a raised free T4 (and free T3) suggests an autonomous (hot) nodule — which carries a much lower malignancy risk — and the next step is radionuclide scintigraphy (technetium-99m pertechnetate or iodine-123) to confirm a hyperfunctioning (tracer-avid) nodule, which generally does not need FNA. Within the normal range, a TSH in the upper half has itself been shown to slightly increase the probability of malignancy.[1]

Step 2 — High-resolution thyroid ultrasound with ACR TI-RADS

High-resolution ultrasound is the single most useful imaging test in thyroid nodule evaluation. The American College of Radiology Thyroid Imaging Reporting and Data System (ACR TI-RADS) assigns points across five feature categories and converts the sum into a risk level (TR1 to TR5) that, combined with nodule size, decides whether to FNA, follow up or ignore.[3]

The FNA / follow-up thresholds by TI-RADS and size: TR1 and TR2 — no FNA. TR3 — FNA if at least 2.5 cm, follow-up if at least 1.5 cm. TR4 — FNA if at least 1.5 cm, follow-up if at least 1 cm. TR5 — FNA if at least 1 cm, follow-up if at least 0.5 cm. Smaller TR3 to TR5 nodules may still be biopsied if there are high-risk clinical features, suspicious nodes, or an extra-thyroidal extension. The pattern of cervical lymph nodes (round, cystic, lost hilum, punctate echogenic foci, calcifications) is itself a major indication for FNA, even when the nodule is small.[3]

Step 3 — Fine-needle aspiration cytology (Bethesda System)

Fine-needle aspiration under ultrasound guidance is the cornerstone of nodule triage. Cytology is reported using The Bethesda System for Reporting Thyroid Cytopathology (TBSRTC), which assigns every thyroid FNA to one of six categories, each carrying an implicit malignancy risk and a linked management recommendation.[4]

The 2017 Bethesda revision updated the implied malignancy risks upward, partly because of the reclassification of non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) — a tumour previously called encapsulated follicular variant papillary carcinoma that is now regarded as very-low-risk, non-malignant and managed by lobectomy alone. This single reclassification reduced apparent cancer rates across Bethesda III, IV and V without changing outcomes.[4]

For the troublesome indeterminate zone (Bethesda III and IV), molecular testing refines the risk and can spare surgery: gene-expression classifiers (Afirma GSC) and next-generation sequencing panels (ThyroSeq, ThyGeNEXT / ThyraMIR) stratify nodules into low-risk (observe) and high-risk (operate) groups, reducing diagnostic lobectomies by around half.[1]

Step 4 — Ancillary tests

• Serum calcitonin — order if medullary cancer is suspected (family history, cytology suggesting MTC, or for some guidelines as a baseline screen). A basal calcitonin over 100 pg/mL (or a stimulated rise after pentagastrin) is highly suggestive; provocative testing with calcium or pentagastrin can be used for borderline values. CEA is a useful tumour-burden marker in MTC and is also raised in anaplastic cancer.[1]
• Cross-sectional CT or MRI of neck and chest — for large nodules, suspected local invasion, retrosternal extension, bulky nodal disease, or anaplastic cancer to map tumour extent and plan surgery. CT with contrast is generally avoided in patients who may receive radioactive iodine, because iodinated contrast loads stable iodine and blocks RAI uptake for weeks; MRI is the preferred alternative in that setting.[1]
• Vocal-cord assessment — flexible laryngoscopy before any thyroid surgery if hoarse.
• Baseline thyroglobulin — measured before definitive treatment of differentiated cancer (it cannot distinguish benign from malignant, but serves as a non-secretion reference after thyroidectomy and RAI).
• RET genetic testing and family screening — for any patient with medullary cancer and first-degree relatives; positive carriers proceed to prophylactic thyroidectomy timed to the mutation risk class.[1]

Management — Resuscitation and Peri-operative Preparation

Most thyroid nodule and cancer work-ups are outpatient. Acute resuscitation is rarely required except for three situations:[1]

1. Airway compromise from a large or anaplastic mass — stridor, respiratory distress, or rapid tracheal compression requires urgent airway assessment (awake fibreoptic intubation may be needed), multidisciplinary oncology and palliative input, and may demand emergency tracheostomy or debulking radiotherapy.
2. Neck haematoma after thyroid surgery — a surgical emergency: the wound must be opened at the bedside to release the clot and relieve airway compression, then the patient returned to theatre for haemostasis.
3. Bilateral recurrent laryngeal nerve injury — post-extubation stridor may demand re-intubation and sometimes tracheostomy. [1]

Peri-operative preparation is high-yield exam material: (a) document vocal-cord function by laryngoscopy before surgery (a pre-existing palsy predicts malignant nerve involvement); (b) check serum calcium, phosphate, vitamin D and parathyroid hormone (PTH) pre-operatively to anticipate and recognise post-operative hypoparathyroidism; (c) render the patient biochemically euthyroid before elective surgery (a hyperthyroid patient is at risk of thyroid storm); (d) for medullary cancer, exclude phaeochromocytoma first (24-hour urinary metanephrines or plasma free metanephrines) to avoid a lethal intra-operative hypertensive crisis; (e) group and save and discuss the risk of tracheostomy, permanent hypocalcaemia and voice change in consent.[1]

Management — Definitive and Stepwise

Definitive management is dictated by the cancer type, the stage, and the recurrence risk of the individual patient. The framework below is built on the 2015 American Thyroid Association guidelines.[1]

Surgery — the central curative modality

Surgical extent ranges from diagnostic lobectomy to total thyroidectomy with neck dissection, chosen on histology and risk.[1]

Radioactive iodine (131-I) ablation

Radioactive iodine-131 ablation is given after total thyroidectomy to destroy residual thyroid tissue and micrometastases, enable sensitive thyroglobulin surveillance, and reduce recurrence in intermediate- and high-risk differentiated cancer. Patients are prepared either by thyroid hormone withdrawal (to raise endogenous TSH) or by recombinant human TSH (rhTSH, Thyrogen) injections, the latter avoiding iatrogenic hypothyroidism. Activity is stratified by recurrence risk — low-activity ablation (around 30 mCi / 1.1 GBq) for low-to-intermediate risk, and higher-activity therapy (100 to 150 mCi) for high-risk disease with nodal metastases, extra-thyroidal extension or distant metastases. RAI has NO role in medullary or anaplastic cancer, because those cells do not concentrate iodine.[1]

TSH suppression with levothyroxine

After total thyroidectomy, all patients require lifelong levothyroxine replacement — typically 1.6 micrograms per kilogram per day as a starting adult dose, adjusted to a risk-adapted TSH target. The 2015 ATA guidance stratifies suppression intensity:[1]

• High-risk cancer — TSH below 0.1 mU/L indefinitely, balancing against bone and cardiac toxicity.
• Intermediate-risk — TSH 0.1 to 0.5 mU/L for several years, then relaxed.
• Low-risk — TSH in the low-normal reference range (0.5 to 2.0 mU/L); aggressive suppression is unnecessary and harmful. [1]

Excess suppression carries real harms: osteoporosis (especially post-menopausal women) and atrial fibrillation (especially older patients) — a compelling reason to relax suppression once recurrence risk has fallen.[1]

Risk-adapted approach and follow-up

The 2015 ATA guidelines formalised dynamic risk stratification: an initial staging estimate (TNM-8 and the ATA response-to-therapy categories) is updated at each follow-up by thyroglobulin trends, neck ultrasound and, when needed, cross-sectional imaging or diagnostic iodine scans. Excellent responders (undetectable stimulated thyroglobulin, normal ultrasound) move to lighter surveillance; biochemical incomplete (rising thyroglobulin) or structural incomplete (imaging-positive disease) responders escalate to further local therapy or systemic treatment.[1]

Targeted and systemic therapy

For RAI-refractory differentiated cancer, multitargeted tyrosine-kinase inhibitors have transformed outcomes. Lenvatinib (24 mg daily) and sorafenib (400 mg twice daily) both improve progression-free survival; lenvatinib produced a striking 18.3 versus 3.6 month median PFS in the SELECT trial.[5]

[1]

For medullary cancer, RET and VEGFR-directed TKIs are the systemic mainstay. Vandetanib (300 mg daily) and cabozantinib (140 mg daily) both prolong progression-free survival; cabozantinib's effect is independent of RET mutation status.[6][7]

[1] [1]

For anaplastic cancer with a BRAF V600E mutation (about half of cases), the combination of dabrafenib plus trametinib (BRAF and MEK inhibition) has produced remarkable responses in a disease that was until recently uniformly fatal within weeks. For RET-mutant medullary cancer, the highly selective RET inhibitors selpercatinib and pralsetinib are emerging as first-line targeted therapy.[2]

Specific Subtypes and Scenarios

Papillary thyroid carcinoma (PTC)

PTC accounts for 80 to 85 percent of thyroid cancers, peaks between 25 and 65, is two to three times more common in women, and is the cancer most strongly linked to childhood neck radiation. Histological variants include the classic type, the follicular variant (now partly reclassified as NIFTP when encapsulated and non-invasive), the aggressive tall-cell, columnar-cell and hobnail variants, and the diffuse sclerosing variant (more aggressive, lymphotropic). Standard treatment of clinically evident PTC is total thyroidectomy plus or minus prophylactic central neck dissection, followed by selective RAI ablation and risk-adapted TSH suppression. Active surveillance of low-risk papillary microcarcinoma (T1a, no invasion, no nodes), pioneered by Japanese and Memorial Sloan Kettering cohorts, is now an accepted alternative to immediate surgery, with very low 10-year progression rates.[1][2]

Follicular thyroid carcinoma (FTC)

FTC accounts for 5 to 10 percent of thyroid cancers, is commoner in iodine-deficient regions, presents slightly later than PTC, and spreads haematogenously to bone and lung. It is defined by capsular and vascular invasion — and so cannot be diagnosed on FNA cytology alone (Bethesda IV triggers diagnostic lobectomy to inspect architecture). It is divided into minimally invasive (excellent prognosis) and widely invasive (worse prognosis). The Hürthle-cell (oncocytic) variant behaves more aggressively, is less RAI-avid and is managed with total thyroidectomy plus RAI and lifelong thyroglobulin surveillance.[1]

Medullary thyroid carcinoma (MTC)

MTC accounts for 2 to 5 percent of thyroid cancers but a disproportionate share of thyroid-cancer deaths, because it is biologically more aggressive and does not respond to RAI or TSH suppression. About 25 percent are hereditary (MEN-2A, MEN-2B, familial MTC) and are caused by germline RET proto-oncogene mutations; the remaining sporadic cases carry somatic RET mutations in roughly half. Every patient with a new diagnosis of MTC must undergo RET genetic testing and family screening, because identifying an asymptomatic RET carrier allows prophylactic thyroidectomy — in infancy for MEN-2B (the most aggressive), in early childhood for MEN-2A and FMTC.[1]

Surgery is the only curative therapy: total thyroidectomy plus routine central (level VI) and ipsilateral lateral (levels II to V) neck dissection, with contralateral lateral dissection if nodal disease is present. Before surgery, exclude phaeochromocytoma (24-hour urinary fractionated metanephrines or plasma free metanephrines) — operating on an unrecognised phaeo in MEN-2 precipitates a lethal hypertensive crisis. Surveillance is with serial calcitonin and CEA (doubling times are strong prognostic markers — calcitonin doubling time under six months is ominous). For progressive metastatic disease, vandetanib, cabozantinib, or the selective selpercatinib (for RET-mutant disease) prolong progression-free survival.[6][7]

Anaplastic thyroid carcinoma (ATC)

ATC accounts for only 1 to 2 percent of thyroid cancers but is responsible for a third to a half of all thyroid-cancer deaths. It arises in older patients (over 60), presents as a rapidly enlarging, hard, painful, fixed neck mass, often with stridor, dysphagia, hoarseness and systemic decline. Histology shows undifferentiated pleomorphic spindle and giant cells; TP53, TERT promoter and beta-catenin mutations are characteristic, and BRAF V600E is often co-present (indicating dedifferentiation from a prior papillary cancer). All ATC are stage IV at diagnosis. Treatment is multimodal where resectable — surgery (rarely curative, often debulking), external-beam radiotherapy and chemotherapy (taxanes such as paclitaxel or docetaxel, sometimes combined with carboplatin). For the BRAF V600E-mutant subgroup, dabrafenib plus trametinib has produced meaningful responses and improved survival. Despite all this, median survival is 4 to 6 months and 5-year survival is under 5 percent; the priority is airway, symptom control and early palliative care.[1][2]

AJCC TNM-8 staging — a major change

The 8th edition (2017, effective 2018) of the AJCC / UICC TNM staging made three changes that materially improve staging accuracy for differentiated thyroid cancer. First, the prognostic age cut-off was moved from 45 to 55 years (reflecting data that age confers a much smaller risk gradient below 55). Second, minimal extra-thyroidal extension was removed from the T3 definition, leaving only tumour size over 4 cm (T3a) or gross strap-muscle invasion (T3b). Third, N1 disease no longer automatically stages an older patient to stage I, since nodal metastasis in well-differentiated PTC confers a much smaller survival penalty than was historically assumed.[1]

Complications and Pitfalls

Disease-related complications

• Local invasion — recurrent laryngeal nerve (hoarseness), trachea (stridor, haemoptysis), oesophagus (dysphagia), especially in anaplastic and advanced medullary disease.
• Nodal and distant metastasis — papillary to cervical nodes and lung; follicular to bone and lung (haematogenous); medullary to nodes, liver and bone; anaplastic widely metastatic.
• Calcitonin syndrome — flushing, secretory diarrhoea in advanced medullary cancer. [1]

Surgical complications

Surgery for thyroid cancer is safe in high-volume hands but carries three classic complications every student must know.[1]

• Recurrent laryngeal nerve (RLN) injury — unilateral causes hoarseness; bilateral causes stridor and may require tracheostomy. Transient in 5 to 10 percent, permanent in 1 to 2 percent with intra-operative nerve monitoring in expert hands.
• Hypoparathyroidism — transient hypocalcaemia in up to 25 percent after total thyroidectomy with central dissection; permanent in 1 to 4 percent. Managed with oral calcium and calcitriol; severe cases need intravenous calcium gluconate. Always check calcium and PTH post-operatively.
• Neck haematoma — rare (under 1 percent) but life-threatening; open the wound at the bedside to release the clot and decompress the airway, then return to theatre.
• Superior laryngeal nerve injury — loss of high-pitch voice and aspiration of liquids.
• Chyle leak, seroma, infection, hypertrophic scar — less common. [1]

Treatment-related complications

• Radioactive iodine — sialadenitis and dry mouth, transient neck pain, nausea, small secondary malignancy risk (notably salivary and leukaemia), and pregnancy / breastfeeding restrictions (avoid pregnancy for 6 to 12 months).
• TSH suppression — osteoporosis (post-menopausal women) and atrial fibrillation (older patients); justify only in high-risk disease.
• TKI therapy — hypertension, diarrhoea, fatigue, hand-foot syndrome, QTc prolongation (vandetanib), proteinuria and bleeding risk. [1]

Classic pitfalls

• Operating on a medullary cancer patient with an undiagnosed phaeochromocytoma — provokes a fatal intra-operative hypertensive crisis. Always exclude phaeo first.
• Diagnosing follicular carcinoma on FNA — impossible; it requires histology of capsular/vascular invasion. Bethesda IV is a diagnostic lobectomy indication.
• Misreading a thyroglobulin level after RAI — must be interpreted with anti-thyroglobulin antibody status (antibodies cause false-low readings) and only after thyroidectomy and ablation.
• Giving RAI for medullary or anaplastic cancer — useless; those cells do not concentrate iodine.
• Treating iodinated-contrast CT as routine in differentiated cancer — iodine loading blocks subsequent RAI for weeks; use MRI if cross-sectional imaging is needed before ablation.
• Over-suppressing TSH in a low-risk older patient — precipitates atrial fibrillation and osteoporosis without benefit. [1]

Prognosis and Disposition

Differentiated thyroid cancer is among the most curable of all solid tumours. Even patients with cervical nodal metastasis have excellent survival — a fact reflected in the AJCC-8 staging change that keeps node-positive disease stage I in patients under 55. Follicular cancer is slightly worse, especially with vascular invasion or distant metastasis. Medullary prognosis is stage- and calcitonin-doubling-time-dependent; MEN-2B and the RET M918T mutation carry the worst outcomes. Anaplastic carcinoma is almost uniformly fatal within months, though the small BRAF-mutant subgroup now benefits dramatically from dabrafenib-trametinib.[1][2]

Disposition is risk-adapted. Most differentiated cancer patients are managed as outpatients with lifelong structured surveillance: six-monthly thyroglobulin and anti-thyroglobulin antibodies, periodic neck ultrasound, and diagnostic whole-body iodine scans when biochemistry or imaging is discordant. Medullary cancer surveillance centres on calcitonin and CEA doubling times, with ultrasound and cross-sectional imaging for rising markers. Anaplastic cancer demands rapid inpatient multidisciplinary management and early palliative care. Benign nodules are observed safely — small low-risk papillary microcarcinomas may even be actively surveilled with excellent long-term outcomes.[1][2]

Special Populations

• Pregnancy — fine-needle aspiration is safe in pregnancy and is indicated for the same ultrasound features as in non-pregnant patients. If a differentiated cancer is found in the first or early second trimester, surgery can usually be deferred to the postpartum unless there are aggressive features (rapid growth, extra-thyroidal extension, nodes); cancers discovered later in pregnancy are almost always observed through delivery. Radioactive iodine is absolutely contraindicated in pregnancy and breastfeeding.[1]
• Children and adolescents — thyroid nodules are less common in children but carry a higher malignancy risk (around 20 to 25 percent). Paediatric papillary cancer is more often disseminated at presentation (larger primaries, more nodal and pulmonary metastasis) but remains highly curable. Children exposed to Chernobyl fallout demonstrated the strong radiation-PTC link. RAI doses and surveillance are weight-adapted.
• Known MEN-2 / RET carriers — prophylactic thyroidectomy is performed before medullary cancer develops, timed by the ATA risk class of the RET mutation: infancy for MEN-2B (highest-risk codons, e.g. M918T), before age 5 years for high-risk MEN-2A, and individualised for lower-risk mutations. Calcitonin surveillance begins early; phaeochromocytoma screening is lifelong.[1]
• The elderly patient with a rapidly growing neck mass — assume anaplastic until proven otherwise; secure the airway, image, biopsy urgently, and involve the multidisciplinary team and palliative care early.
• Patients on amiodarone — the iodine load can precipitate both hyper- and hypothyroidism and cause nodular change; check thyroid function before and during amiodarone.

Evidence, Guidelines and Regional Differences

Key controversies

• Over-diagnosis and over-treatment — the steep rise in thyroid cancer incidence from increased imaging has led to concerns about overtreatment of indolent papillary microcarcinoma. Active surveillance of low-risk T1a tumours, molecular testing to reduce diagnostic lobectomy, and the NIFTP reclassification are all responses.
• Extent of surgery — total thyroidectomy versus lobectomy for low-risk unilateral disease remains debated; lobectomy avoids bilateral complications but complicates RAI and thyroglobulin surveillance.
• RAI in low-risk disease — increasingly avoided in patients at very low recurrence risk, to spare toxicity.
• TSH suppression intensity — relaxed for low-risk disease to avoid bone and cardiac toxicity.
• Prophylactic central neck dissection — its routine use in clinically node-negative papillary cancer varies between centres; the ATA recommends it be considered, not mandated.[1]

Exam Pearls and High-Yield Minutiae

Quick self-test — what is the first test in a thyroid nodule, and why?

Serum TSH. A normal or raised TSH prompts ultrasound (TI-RADS) and selective FNA; a suppressed TSH points to an autonomous (hot) nodule with a low malignancy risk, which is then assessed by radionuclide scintigraphy. Skipping TSH means you cannot interpret the rest of the work-up.[1]

Quick self-test — why can follicular carcinoma NOT be diagnosed on FNA?

Because FTC is defined by capsular and vascular invasion, which are architectural features — FNA samples cells, not the relationship of the tumour to its capsule and vessels. Bethesda IV (follicular neoplasm) therefore triggers diagnostic lobectomy for histological assessment. (Papillary, in contrast, is diagnosable cytologically by its nuclear features.)[1][4]

Quick self-test — what MUST you exclude before operating on a medullary thyroid cancer?

A phaeochromocytoma (MEN-2). Operating on an unrecognised phaeo precipitates a fatal intra-operative hypertensive crisis. Screen with 24-hour urinary fractionated metanephrines or plasma free metanephrines before any surgery; if positive, the phaeochromocytoma is resected first (usually after alpha-blockade).[1][6]

Exam application bank (NEET-PG / INICET)

One-line answer

Thyroid nodules are very common but mostly benign — palpable in around 5 percent of adults and seen on ultrasound in 30 to 50 percent — yet only 5 to 10 percent are malignant. The clinical task is to identify that minority through ultrasound risk-stratification (ACR TI-RADS) and fine-needle aspiration cytology (Bethesda System), guided by clinical risk (neck radiation, family history, rapid growth, hoarseness, fixed nodule, lymphadenopathy). The four main thyroid cancers are papillary (commonest, around 80 percent; excellent prognosis; BRAF V600E, RET-PTC, psammoma bodies, orphan Annie-eye nuclei), follicular (10 percent; vascular and capsular invasion; haematogenous spread to bone and lung; RAS mutation), medullary (5 percent; parafollicular C cells; calcitonin; MEN-2; RET proto-oncogene) and anaplastic (1 to 2 percent; undifferentiated; elderly; survival measured in months). Differenti

Worked stems (answer without another resource)

Stem 1 — Classic presentation. Map symptoms to mechanism; name the first investigation and first treatment step with dose/route if drug therapy is standard. [1]

Stem 2 — Unstable / complicated. List red flags that force immediate resuscitation, theatre, ICU, antidote, or reperfusion — and what you do in the first 15 minutes. [1]

Stem 3 — Atypical group. Elderly, pregnancy, child, or immunocompromised: how presentation and thresholds change. [1]

Stem 4 — Differential trap. Name the three closest mimics and one discriminator for each. [1]

Stem 5 — Disposition. Who goes home with safety-netting, who is admitted, who needs HDU/ICU/theatre, and what follow-up is mandatory. [1]

Rapid viva checklist

1. Definition + classification
2. Pathophysiology chain
3. Bedside signs / criteria
4. Score with exact components (if any)
5. Emergency bundle
6. Definitive therapy with doses
7. Complications of disease and of treatment
8. Special populations
9. Guideline/trial name if classic
10. Three exam traps

Coverage self-check

If you cannot answer any stem above from this page alone, re-read the matching section — the page is intended to be self-sufficient for final-prof and NEET-PG/INICET questions on Thyroid Nodules & Thyroid Cancer.

[1]

References

1. [1]Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer Thyroid, 2016.PMID 26462967
2. [2]Grani G, Sponziello M, Filetti S, Durante C. Thyroid nodules: diagnosis and management Nat Rev Endocrinol, 2024.PMID 39152228
3. [3]Tessler FN, Middleton WD, Grant EG, et al. ACR Thyroid Imaging, Reporting and Data System (TI-RADS): White Paper of the ACR TI-RADS Committee J Am Coll Radiol, 2017.PMID 28372962
4. [4]Cibas ES, Ali SZ. The 2017 Bethesda System for Reporting Thyroid Cytopathology Thyroid, 2017.PMID 29091573
5. [5]Schlumberger M, Tahara M, Wirth LJ, et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer N Engl J Med, 2015.PMID 25671254
6. [6]Wells SA Jr, Robinson BG, Gagel RF, et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial J Clin Oncol, 2012.PMID 22025146
7. [7]Elisei R, Schlumberger MJ, Muller SP, et al. Cabozantinib in progressive medullary thyroid cancer J Clin Oncol, 2013.PMID 24002501